Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution

American Journal of Surgical Pathology

Volumn 37, Issue 1, 2013, Pages 120-127

  Clay, Michael R ^a   Iberri, David J ^a   Bangs, Charles D ^a   Cherry, Athena ^a   Jensen, Kristin C ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

ambiguous; equivocal; FISH; HER2; IHC; trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; FACTUAL DATABASE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MASTECTOMY; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; REPRODUCIBILITY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84871621206     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826ab19d     Document Type: Article

References (14)

1. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: An erb-B-related gene encoding a 185, 000-Mr tumour antigen. Nature. 1984;312:513-516.
2. Ross JS, Slodkowska EA, Symmans WF, et al. The HER2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
3. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131: 18-43.
4. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 1992;89:5321-5325.
5. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: A single institution experience. Diagn Mol Pathol. 2007;16:207-210.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-792.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histologic grading in breast cancer: experience from a large study with long-term follow-up. Histopathology. 2002;41(3A):154-161.
8. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. National center for biotechnology information. U.S. national library of medicine, 06 Dec. 2010. Web. 1 Aug. 2011. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3005907.
9. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer, stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916-921.
10. Jensen KC, Turbin DA, Leung S, et al. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 2008;112:453-459.
11. Paik S, Kim C, Wolmark N. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. N Engl J Med. 2008; 358:1409-1411.
12. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
13. Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixation type on HER2/neu immunohis-tochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011;136:754-761.
14. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science. 1987;235:177-182.